Rx License-Rx

24-10624-TpNCS

Ionizable Lipid Nanoparticles with Low Immunogenicity Which Enable Repeated Administrations of mRNAs Encoding Gene Editors, Tumor Neoantigens, and Vaccine Payloads.

Using Mannich reaction-based combinatorial libraries to identify ionizable lipids for low-immunogenic and high-efficiency mRNA delivery. Problem: Lipid nanoparticle (LNP)-based delivery systems for mRNA-based therapeutics have recently demonstrated their clinical success in applications such as ONPATTRO® and the Pfizer/BioNTech and Moderna COVID-19 vaccines. However, existing LNP-based delivery systems have intrinsic high immunogenicity, restricting the mRNA therapeutics' protein expression levels, durability, and broader applications (e.g., redosing). Solution: The inventors constructed a series of Mannich reaction-based combinatorial libraries and used high throughput in vitro and in vivo screenings to identify the top-performing ionizable lipid, C-a16. This antioxidant lipid effectively reduces cellular inflammatory responses, extends intracellular protein expression duration, and mitigates intracellular reactive oxygen species...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Oncology

Indication: COVID-19

Modality: Small Molecule

Focus tags: Oncology, Immunology, Inflammation, Cardiometabolic, Infectious Disease

Technology tags: Small Molecule, Biologic, Cell/Gene Therapy, Drug Delivery

Mechanism:

Development stage: Early / Discovery

Patent status: Provisional Filed

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be early / discovery and is associated with University of Pennsylvania. The practical first use case is COVID-19. Public description: Using Mannich reaction-based combinatorial libraries to identify ionizable lipids for low-immunogenic and high-efficiency mRNA delivery. Problem: Lipid nanoparticle (LNP)-based delivery systems for mRNA-based therapeutics have recently.

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: COVID-19

Study design: Biomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.